PT - JOURNAL ARTICLE AU - Ferrari, Gabriele AU - Loayza, Richard AU - Azari, Ava AU - Geijer, Håkan AU - Cao, Yang AU - Carlsson, Roland AU - Bojö, Leif AU - Samano, Ninos AU - Souza, Domingos TI - Superior long-term patency of no-touch vein graft compared to conventional vein grafts in over 1500 consecutive patients AID - 10.1101/2024.02.19.24303064 DP - 2024 Jan 01 TA - medRxiv PG - 2024.02.19.24303064 4099 - http://medrxiv.org/content/early/2024/02/21/2024.02.19.24303064.short 4100 - http://medrxiv.org/content/early/2024/02/21/2024.02.19.24303064.full AB - Objectives To evaluate the long-term angiographic patency of saphenous vein grafts (SVG) harvested using the no-touch technique compared to the conventional technique.Methods This was a single-center, retrospective, cohort study. The inclusion criteria were individuals who underwent a CABG (coronary artery bypass grafting) between January 1995 and July 2020, and who successively needed a clinically-driven angiography. The primary endpoint was long-term patency. The secondary endpoints were differences in patency based on sub-group analysis (single vs. sequential graft, divided by target vessel).Results The study included 1520 individuals (618 no-touch, 825 conventional and 77 arterial grafts). The mean clinical follow-up time was 8.4 years ± 5.5 years. The patency per patient was 70.7% in the no-touch grafts vs. 46.7% in the conventional grafts (p < 0.001, OR = 2.8). The graft patency was 75.9% in the no-touch grafts vs. 62.8% in the conventional grafts (p < 0.001, OR= 1.8).Conclusions The no-touch vein grafts were associated with statistically significantly higher patency at long-term compared to the conventional grafts.Clinical Trial Registration NCT04656366, 7 December 2020Clinical Perspective- What is new? ➣ The largest follow-up of the patency of no-touch vein grafts in the international literature.➣ Patients with a no-touch vein graft had significantly better patency (p < 0.001) at mean follow-up of more than 8 years.- What are the clinical implications? ➣ Consequent reduction in cardiovascular events after no-touch vein graft.➣ Benefits at individual level due to fewer episodes of re-angina and myocardial infarction, and fewer coronary interventions.➣ Benefits at community level due to fewer re-hospitalizations and a reduction in healthcare costs.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinical Trial Registration: NCT04656366, 7 December 2020Funding StatementThis work was supported by Region Örebro County through the regional research board (grant OLL- OLL-935188, 18 January 2020).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Regional Ethics Review Board in Uppsala (Regionala etikprövningsnämnden i Uppsala). Dnr 2020/03890.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yeshttps://classic.clinicaltrials.gov/ct2/show/NCT04656366Aarterial graftBMSbare metal stentCconventionalCABGcoronary artery bypass graftingDAdiagonal arteryDAPTdouble antiplatelet therapyDESdrug-eluting stentEFejection fractionFFRfractional flow reserveiFRinstantaneous wave-free ratioIQRinterquartile rangeLADleft anterior descending arteryLITAleft internal thoracic arteryMAmarginal arteryMACEmajor adverse cardiac eventsMImyocardial infarctionNTno-touchORodds ratioPCIpercutaneous coronary interventionRCAright coronary arteryRITAright internal thoracic arterySDstandard deviationSVGsaphenous vein graftTIMIthrombolysis in myocardial infarctionTVRtarget vessel revascularization